Kymera
targeting degrader advantage clinical validation and human genetics risking | Kymera
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
20 of 105
Similar slides by Kymera
See diffirences between slides (animation)
Investor Presentation
December 2023
degrading best approach to block driven inflammation degrader advantage | Kymera
Investor Presentation
November 2023
degrading best approach to block driven inflammation | Kymera
Investor Presentation
August 2023
degrading best approach to block driven inflammation on | Kymera
Investor Presentation
June 2023
degrading best approach to block driven inflammation on | Kymera
Related slides by other companies
BenevolentAI
Investor Presentation
October 2022
portfolio key in points ben atopic dermatitis ben ulcerative colitis ben pipeline depth and progression inflection | BenevolentAI
AstraZeneca
Results
November 2024
antibody rheumatoid arthritis | AstraZeneca
BenevolentAI
Investor Day
September 2022
ben atopic dermatitis atopic dermatitis is the most common chronic in skin disease characterized by intensely itchy red and swollen skin affects of children and up to of adults approximately of all cases present with mild moderate disease severity prevalence is rising with market value in forecast to exceed billion skin in and chronic pruritus associated with atopic dermatitis negatively impact quality of life and psychosocial well being clear unmet need in mild to moderate patient segment for treatment addressing itch and in without side effects of steroids | BenevolentAI
BenevolentAI
Investor Day
September 2022
portfolio key in points ben atopic dermatitis ben ulcerative colitis ben pipeline depth and progression inflection | BenevolentAI
Other recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights